Kodiak Sciences Inc. (KOD)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Victor Perlroth M.D.
|
Co-Founder, Chairman, CEO & President | 1.58M | -- | 1974 |
|
Mr. John A. Borgeson CPA, M.B.A.
|
Executive VP, CFO & Secretary | 937.16k | -- | 1963 |
|
Mr. Wayne To M.Phil.
|
Chief Technology Officer | -- | -- | -- |
|
Dr. Dolly S. Chang M.D., M.P.H., Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Dr. Hong Liang Ph.D.
|
Senior Vice President of Development | 300.71k | -- | 1972 |
|
Dr. Stephen Raillard Ph.D.
|
Senior Vice President of Chemical Development & Manufacturing | -- | -- | -- |
|
Ms. Almas Qudrat M.Sc.
|
Chief Quality Officer | -- | -- | -- |
|
Dr. J. Pablo Velazquez-Martin M.D.
|
Chief Medical Officer | -- | -- | -- |
|
Dr. Laurent Ducay Ph.D.
|
Senior VP of Biologics Development & Manufacturing | -- | -- | -- |
Kodiak Sciences Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 141
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Kodiak Sciences Inc. Earnings Date
